Alteration of radiation-induced hematotoxicity by amifostine

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 4, 2001, Pages 947-951

  Momm, Felix ^a   Bechtold, Christine ^a   Rudat, Volker ^b   Strnad, Vratislav ^c   Tsekos, Alexander ^a   Fischer, Karin ^a   Henke, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Amifostine; Hematotoxicity; Leukocytes; Radiotherapy

Indexed keywords

BLOOD; CELLS; DRUG PRODUCTS; HEMOGLOBIN; PATIENT MONITORING; RADIOTHERAPY; TOXICITY; TUMORS;

BLOOD COUNTS;

RADIATION PROTECTION;

AMIFOSTINE; HEMOGLOBIN;

ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HEMOGLOBIN DETERMINATION; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MOUTH CARCINOMA; MULTICENTER STUDY; NEUTROPHIL; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AMIFOSTINE; BLOOD PLATELETS; CARCINOMA, SQUAMOUS CELL; GRANULOCYTES; HEAD AND NECK NEOPLASMS; HEMOGLOBIN A; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; LYMPHOCYTES; PLATELET COUNT; PROSPECTIVE STUDIES; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE;

EID: 0035889329     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01710-2     Document Type: Article

References (24)

1. Future development of amifostine in cancer treatment
2. Amifostine and chemotherapy-related thrombocytopenia
3. R) in patients treated with carboplatin
4. The need for cytoprotection
5. Use of amifostine in bone marrow purging
6. R)
7. Phase I/II trials of WR-2721 and cis-platinum
8. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity
9. Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721
10. Protective effect of amifostine on dental health after radiotherapy of the head and neck
11. R)
12. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer
13. Amifostine and radiation therapy; Past, present, and future
14. Protection by WR-2721 of human bone marrow function following irradiation
15. R)
16. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
17. Cytoprotection with amifostine in radiotherapy or combined radio-chemotherapy of head and neck cancer
18. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment
19. Cytoprotection with amifostine in the simultaneous radio-chemotherapy of recurrent head and neck cancer
20. Amifostine-a radioprotector in locally advanced head and neck tumors
21. Results of definitive combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine administration
22. Acute toxicity of postoperative radiochemotherapy with amifostine vs radiochemotherapy alone in head and neck cancer patients; Preliminary results of a randomized trial
23. A Phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies
24. Chronic myeloproliferative syndromes